Taysha Gene Therapies (TSHA) Net Equity Issued and Repurchased (2020 - 2022)
Taysha Gene Therapies (TSHA) posted Net Equity Issued and Repurchased of $40000.0 for Q2 2022, down 99.94% sequentially from $66.2 million in Q4 2020.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) Net Equity Issued and Repurchased (2020 - 2022) Analysis & Trends
Taysha Gene Therapies has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $40000.0 in Q2 2022.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $40000.0 in Q2 2022, while the trailing twelve-month figure through Sep 2023 was $40000.0 (down 99.95% YoY) and the FY2023 annual result came in at $500000.0, down 95.7% from the prior year.
- Net Equity Issued and Repurchased eased to $40000.0 in Q2 2022 per TSHA's latest filing, from $66.2 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $66.2 million in Q4 2020 and troughed at $40000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 16.08 Mn |
| Jun 30, 2022 | 40,000.00 |
| Sep 30, 2020 | 77.22 Mn |
| Jun 30, 2020 | 600,000.00 |
| Mar 31, 2020 | 18.00 Mn |